Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MS vision loss mystery: is it scarring or cell death?

NCT ID NCT02543788

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at 39 people with multiple sclerosis who have chronic vision problems. Researchers used eye exams, scans, and electrical tests to see if the vision loss is caused by nerve scarring (demyelination) or nerve cell death (degeneration). The goal is to better understand the root cause so doctors can predict and manage vision decline more effectively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict and manage vision problems in MS patients by identifying the underlying cause.
What could go wrong
This is a small observational study with only 39 participants, so results may not apply to all MS patients. It aims to understand the disease, not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

39 people

The number who actually took part.

Started

Sep 2014

Finished

Aug 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion criteria for patients * All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010). * All patients may present a chronic visual complaint. * All patients may present mild to moderate chronic optic neuropathy (cf infra) * All patients may not have recent acute optic neuritis (\<2 years) * All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee. * Age: \> 18 * Able to understand the instructions * Having a health coverage * Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria: 1. Far Visual Acuity (ETDRS charts, 100% contrast) \< 85 letters 2. Far Visual Acuity (ETDRS charts, 2.5% contrast) \< 60 letters 3. Mean visual field defect on static perimetry\> 2dB 4. Mean pRNFL in OCT \< 80 µ. 5. Color vision score \> 35 6. Disc pallor Diagnosis of mild to moderate optic neuropathy * Far Visual Acuity (ETDRS charts, 100% contrast) \>70 letters Diagnosis of chronic optic neuropathy * Stable or worsening of visual acuity, visual field and/or RNFL in OCT, at 6 month of interval \- Inclusion criteria for controls * Age \> 18 years * Visual acuity score (ETDRS) \> 85 * Able to understand the instructions * Having a health coverage * Informed and consenting to give his written consent Exclusion Criteria: * Non inclusion criteria for patients. * Ophthalmological * Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…) * Ocular instability in primary position of gaze * Neurological * Ongoing seizure * Severe handicap that does not allow sitting down position for 1 hour * General * Unstable medical state * Severe renal insufficiency * Allergy to gadolinium * Claustrophobia * Implanted electrical stimulator (pace maker) * Metallic prosthesis or orthesis, cochlear implants * Intraocular foreign material * Pregnancy (on questioning) * Tutelage or any legal protection measure * Non inclusion criteria for controls * Any ophthalmological disorder that could impair corrected visual acuity * Any neurological disorder * MRI contraindication * Allergy to gadolinium * Severe renal insufficiency * Claustrophobia * Implanted electrical stimulator (pace maker) * Metallic prosthesis or orthesis, cochlear implants * Intraocular foreign material * Pregnancy (on questioning) * Tutelage or any legal protection measure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic optic neuropathy in multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON

    France, BRON, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.